On the basis of these observations, especially we detected a high frequency of XAF1 DNA methylation in gastric cancer tissues (83.2%), we decided to explore the possibility to use XAF1 promoter methylation in the serum as a biomarker in gastric cancer patients. The gene discussed is XAF1; the disease is gastric cancer.